Novartis
NEWS
Novartis managed to bridge the gap between evidence of efficacy and value in this space with a variety of value-based pricing plans developed with regional payers.
The Foundation will offer funding for development of the therapy.
Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
While companies around the globe reduce staff amidst economic upheaval, there’s at least one industry on the rise - life sciences. Here’s who’s breaking ground on expansion projects.
The pharmaceutical industry continues to demonstrate its willingness to team up in the ongoing combat against the global COVID-19 pandemic.
Novartis shares were down by 4.4% as the market opened, following the announcement on its earnings call of a disappointing $2.1 billion in net profits and $0.92 earnings per share for 4Q20, below most investor estimates.
Novartis plunked down $650 million in upfront payment for BeiGene’s Tislelizumab, which is already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
JOBS
IN THE PRESS